
|Slideshows|December 6, 2014
Are We Overtreating DCIS?
Author(s)Laura J. Esserman, MD, MBA
With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Achieving a “Functional Cure” With Multiple Myeloma Therapy
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency
4
130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
5

















































